Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ACT-01 is a peptidomimetic first-in-class disease-modifying treatment for multiple sclerosis (MS) and acute optic neuritis, the latter with orphan drug designation by the US FDA and the EMA in the EU.
Lead Product(s): ACT-01
Therapeutic Area: Neurology Product Name: ACT-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2021
Details:
The study results show that the ACT-03, when administered in animal models over one week, can slow the progression of the disease by reducing the severity and number of spontaneous seizures (up to seven weeks after initial drug administration).
Lead Product(s): IPR-179
Therapeutic Area: Neurology Product Name: ACT-03
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021